Advertisement

Orthopedic Oncologic Surgical Specimen Management and Surgical Pathology

  • A. Kevin Raymond
  • Alexander J. Lazar
Chapter
Part of the MD Anderson Cancer Care Series book series (MDCCS)

Chapter Overview

The pathologist is an integral member of the multidisciplinary team ­central to the successful treatment of bone tumors. The role of the pathologist is to provide morphology-derived information pertaining to diagnosis and status of disease. Communication between all members of this team is vital at all junctures of workup and treatment. During the evaluation of biopsies, critical information from the history, physical examination, and imaging studies should be taken into account and integrated with histological observations to ensure a correct diagnosis. Later on during the course of treatment, the pathologist is called upon to advise the surgeon as to the status of resection margins and adequacy of surgery. And later still, the pathologist provides the medical oncologist with an assessment of the response to preoperative chemotherapy.

In each case, the evaluation of bone specimens requires a systematic approach to specimen preparation and analysis. Mineralization is intrinsic to the structure and function of bone. However, it adds a significant degree of difficulty to bone specimen management; osseous tissues are not easily dissected or cut using traditional techniques. Special methods are required for analyzing bone specimens and sarcomas of bone. Although complex and time consuming, the procedures, when carried out correctly, will reward the pathologist and clinician with accurate, reliable information that provides insight into diagnosis, classification, staging, and treatment efficacy.

Keywords

Bone Tumor Ewing Sarcoma Aneurysmal Bone Cyst Bone Specimen Preoperative Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Readings

  1. Avigad S, Cohen IJ, Zilberstein J, et al. The predictive potential of molecular detection in nonmetastatic Ewing family of tumors. Cancer. 2006;100:1053–8.CrossRefGoogle Scholar
  2. Ayala AG, Raymond AK, Ro JY, Carrasco CH, Fanning CV, Murray JA. Needle biopsy of primary bone lesions. M.D. Anderson experience. Pathol Annu 1989;24:219–51.PubMedGoogle Scholar
  3. Bjonsson J, McCleod RA, Unni KK, Ilstrup DM, Pritchard DJ. Primary chondrosarcoma of long bones and limb girdles. Cancer. 1998;83:2105–19.CrossRefGoogle Scholar
  4. Dahlin DC, Unni KK. Osteosarcoma of bone and its important recognizable varieties. Am J Surg Pathol. 1977;1:61–72.PubMedCrossRefGoogle Scholar
  5. Dahlin DC, Coventry MB, Scanlon PW. Ewing’s sarcoma: a critical analysis of 165 cases. J Bone Joint Surg Am. 1961;43:185–92.PubMedGoogle Scholar
  6. Dayton AS, Ro JY, Schwartz MR, Ayala AG, Raymond AK. Raymond’s paragraph system: an alternative format for the organization of gross pathology reports and its implementation in an academic teaching hospital. Arch Pathol Lab Med. 2009;133:298–302.PubMedGoogle Scholar
  7. de Alva E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol. 1998;16:1248–55.Google Scholar
  8. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162–5.PubMedCrossRefGoogle Scholar
  9. Dorfman H, Czerniak BA (1998) Bone tumors. Mosby, Saint LouisGoogle Scholar
  10. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 197740:818–31.PubMedCrossRefGoogle Scholar
  11. Fletcher CDM, Unni KK, Mertens F (eds). World Health Organization classification of tumours. Tumours of soft tissue and bone. Pathology & genetics. IARC Press, Lyon: 2002.Google Scholar
  12. Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol. 2005;29:1025–33.PubMedGoogle Scholar
  13. Hallor KH, Micci F, Meis-Kindblom JM, et al. Fusion genes in angiomatoid fibrous histiocytoma. Cancer Lett. 2006;251:158–63.PubMedCrossRefGoogle Scholar
  14. Jaffe HL, Lichtenstein L. Benign chondroblastoma of bone: a reinterpretation of the so-called calcifying or chondromatous giant cell tumor of bone. Am J Pathol. 1942;18:969–91.PubMedGoogle Scholar
  15. Lazar A, Abruzzo LV, Lee S, Pollock RE, Czerniak BA. Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. Arch Pathol Lab Med. 2006;130:1199–207.PubMedGoogle Scholar
  16. Lewis MM, Kenan S, Yabut SM, Norman A, Steiner G. Periosteal chondroma. A report of ten cases and review of the literature. Clin Orthop. 1990;256:185–92.PubMedGoogle Scholar
  17. Lichtenstein L, Jaffe HL. Chondrosarcoma of bone. Am J Pathol. 1943;19:553–89.PubMedGoogle Scholar
  18. Nakashima Y, Unni KK, Shives TC, Swee RG, Dahlin DC. Mesenchymal chondrosarcoma of bone and soft tissue: a review of 111 cases. Cancer. 1986;57:2444–53.PubMedCrossRefGoogle Scholar
  19. Raymond AK, Ayala AG. Specimen management after osteosarcoma chemotherapy. Contemp Issues Surg Pathol. 1988;11:157–83.Google Scholar
  20. Raymond AK, Chawla SP, Carrasco CH, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol. 1987;4:212–36.PubMedGoogle Scholar
  21. Romeo S, Dei Tos AP. Soft tissue tumors associated with EWSR1 translocation. Virchows Arch. 2010;456:219–34.PubMedCrossRefGoogle Scholar
  22. Rubin BP, Antonescu CR, Gannon FH, et al. Protocol for the examination of specimens from patients with tumors of bone. Washington DC: College of American Pathologists; 2011. Available at http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/Bone_11protocol.pdf. Accessed 19 Jun 2012.
  23. Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA. Ewing sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009;10:126–40.PubMedCrossRefGoogle Scholar
  24. Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing sarcoma. Oncogene. 2010;29:4504–16.PubMedCrossRefGoogle Scholar
  25. Turcotte RE, Kurt AM, Sim FH, Unni KK, McLeod RA. Chondroblastoma. Hum Pathol 1993;24:944–9.PubMedCrossRefGoogle Scholar
  26. Unni KK, Inwards CY. Dahlin’s bone tumors: general aspects and data on 10,165 Cases, 6th edn. Wolters Kluwer/Lippincott, Williams & Wilkins, Philadelphia: 2009.Google Scholar
  27. Unni KK, Inwards CY, Bridge JA, Kindblom LG, Wold LE. Tumors of the bones and joints. AFIP atlas of tumor pathology. Series 4; Fascicle 2. ARP Press, Silver Spring: 2005.Google Scholar
  28. van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2010;28:1989–94.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.BrunswickUSA
  2. 2.retired from Section of Orthopaedic Pathology, Department of Pathology, Division of Pathology and Laboratory MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Pathology, Division of Pathology and Laboratory MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Department of Dermatology, Division of Internal MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations